| 22th Oct 2021 | Scientists at University Medical Centre Ljubljana used our scioDiscover platform for a biomarker identification in endometriosis:

"Discovery proteomics using antibody microarrays that covered 1360 proteins identified 16 proteins with different levels in cases versus the control patients. The validation using an ELISA approach confirmed significant differences in the levels of cartilage oligomeric matrix protein (COMP) and transforming growth factor-β-induced protein ig-h3 (TGFBI) and nonsignificant differences in angiotensinogen (AGT). "

 Janša, V. et al. (2021) ‘Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new candidate biomarkers for endometriosis’, Scientific Reports, 11:20870. doi: 10.1038/s41598-021-00299-2. 

| Oct 2021 | In a study led by University of Luxembourg and OrganoTherapeutics SARL-S we used our scioPhospho assay to analyse the reaction of a brain organoid model for Parkinson's disease to certain treatments.

Jarazo, J. et al. (2021) ‘Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxy...’, Movement Disorders, in press: doi: 10.1002/mds.28810 (Please get in touch for fulltext).

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8⁺SLAMF7⁺ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8⁺SLAMF7⁺ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8⁺SLAMF7⁺ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8⁺SLAMF7⁺ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD  platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:

"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."

B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.

| Dec 2020 | Scientists at University of Sassari used our scioPhospho  platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.